APTX · Aptinyx Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue | - | $1.00M | $1.56M | $3.67M | $4.96M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $42.75M | $55.44M | $32.84M | $44.33M | $31.64M |
| SG&A | $19.82M | $20.09M | $19.49M | $18.95M | $5.55M |
| Total Operating Expenses | $62.57M | $75.53M | $52.33M | $63.28M | $37.20M |
| D&A | $122.0K | $526.0K | $421.0K | $455.0K | $405.0K |
| Operating Income | ($62.57M) | ($74.53M) | ($50.77M) | ($59.61M) | ($32.23M) |
| Interest Expense | $512.0K | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($64.85M) | ($74.89M) | ($50.05M) | ($57.41M) | ($53.28M) |
| EPS - Basic | ($0.96) | ($1.02) | - | - | - |
| EPS - Diluted | ($0.96) | ($1.02) | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | $56.20M | $106.12M | $141.03M | $98.85M | $150.64M |
| Accounts Receivable | - | - | $257.0K | $444.0K | $578.0K |
| Inventory | - | - | - | - | - |
| Accounts Payable | $724.0K | $622.0K | $1.21M | $1.55M | $1.89M |
| Current Assets | $64.03M | $114.74M | $149.60M | $105.11M | $153.25M |
| Total Assets | $66.68M | $114.93M | $150.61M | $106.48M | $155.61M |
| Current Liabilities | $6.29M | $5.69M | $4.58M | $4.90M | $5.88M |
| Long-term Debt | $22.11M | $14.15M | - | - | - |
| Total Liabilities | $28.40M | $20.17M | $4.70M | $5.17M | $6.30M |
| Stockholders' Equity | $38.28M | $94.76M | $145.91M | $101.31M | $149.31M |
| Retained Earnings | ($352.74M) | ($287.89M) | ($213.00M) | ($162.95M) | ($105.54M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($59.68M) | ($63.42M) | ($42.36M) | ($52.09M) | ($32.73M) |
| Investing Cash Flow | - | $121.0K | ($214.0K) | ($39.0K) | ($1.58M) |
| Financing Cash Flow | $9.75M | $28.33M | $84.67M | $192.0K | $106.37M |
| CapEx | - | - | $214.0K | $43.0K | $1.58M |
| Free Cash Flow | - | - | ($42.57M) | ($52.13M) | ($34.31M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | -7453.4% | -3245.8% | -1624.8% | -649.6% |
| EBITDA margin | - | -7400.8% | -3218.9% | -1612.4% | -641.4% |
| Net margin | - | -7488.6% | -3200.3% | -1564.7% | -1073.8% |
| Free cash flow margin | - | - | -2721.9% | -1420.8% | -691.5% |
| FCF / Net income | - | - | 0.85 | 0.91 | 0.64 |
| R&D / Revenue | - | 5544.4% | 2099.4% | 1208.2% | 637.7% |
| SG&A / Revenue | - | 2009.0% | 1246.4% | 516.5% | 111.9% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -97.2% | -65.2% | -33.2% | -53.9% | -34.2% |
| Return on equity | -169.4% | -79.0% | -34.3% | -56.7% | -35.7% |
| Return on invested capital | -81.8% | -54.1% | - | - | - |
| Liquidity | |||||
| Current ratio | 10.18 | 20.18 | 32.64 | 21.47 | 26.04 |
| Quick ratio | 10.18 | 20.18 | 32.64 | 21.47 | 26.04 |
| Cash ratio | 8.93 | 18.66 | 30.77 | 20.19 | 25.60 |
| Leverage | |||||
| Debt / Equity | 0.58 | 0.15 | - | - | - |
| Debt / Assets | 0.33 | 0.12 | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -122.2x | - | - | - | - |
| Equity multiplier | 1.74 | 1.21 | 1.03 | 1.05 | 1.04 |
| Liabilities / Assets | 0.43 | 0.18 | 0.03 | 0.05 | 0.04 |
| Efficiency | |||||
| Asset turnover | - | 0.01 | 0.01 | 0.03 | 0.03 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | 60d | 44d | 43d |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | -36.1% | -57.4% | -26.1% | - |
| Revenue CAGR (3y) | - | -41.4% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 16.1% | -46.8% | 14.8% | -84.9% | - |
| Net income growth (YoY) | 13.4% | -49.6% | 12.8% | -7.7% | - |
| EPS growth (YoY) | 5.9% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | 18.3% | -51.9% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -59.6% | -35.1% | 44.0% | -32.1% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Aptinyx Inc. against the 5 most active filers in the same SIC group.